Quinn Opportunity Partners LLC Sells 72,973 Shares of Ophthotech Corporation (NASDAQ:OPHT)

Quinn Opportunity Partners LLC lessened its stake in Ophthotech Corporation (NASDAQ:OPHT) by 64.0% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 41,000 shares of the biopharmaceutical company’s stock after selling 72,973 shares during the period. Quinn Opportunity Partners LLC owned 0.11% of Ophthotech Corporation worth $105,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Teachers Advisors LLC increased its position in Ophthotech Corporation by 6.1% in the 4th quarter. Teachers Advisors LLC now owns 52,243 shares of the biopharmaceutical company’s stock valued at $252,000 after acquiring an additional 2,999 shares during the period. Geode Capital Management LLC increased its position in Ophthotech Corporation by 3.2% during the 1st quarter. Geode Capital Management LLC now owns 240,571 shares of the biopharmaceutical company’s stock worth $880,000 after purchasing an additional 7,501 shares during the period. Vanguard Group Inc. increased its position in Ophthotech Corporation by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 2,813,720 shares of the biopharmaceutical company’s stock worth $10,298,000 after purchasing an additional 14,766 shares during the period. SG Americas Securities LLC increased its position in Ophthotech Corporation by 67.7% during the 1st quarter. SG Americas Securities LLC now owns 50,867 shares of the biopharmaceutical company’s stock worth $186,000 after purchasing an additional 20,537 shares during the period. Finally, JPMorgan Chase & Co. increased its position in Ophthotech Corporation by 21.7% during the 1st quarter. JPMorgan Chase & Co. now owns 140,040 shares of the biopharmaceutical company’s stock worth $513,000 after purchasing an additional 24,986 shares during the period. Hedge funds and other institutional investors own 61.40% of the company’s stock.

In related news, Chairman David R. Guyer sold 17,678 shares of the firm’s stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $2.58, for a total transaction of $45,609.24. Following the transaction, the chairman now owns 37,692 shares in the company, valued at $97,245.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 33,909 shares of company stock worth $87,485 in the last quarter. Company insiders own 2.00% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Quinn Opportunity Partners LLC Sells 72,973 Shares of Ophthotech Corporation (NASDAQ:OPHT)” was reported by BBNS and is the property of of BBNS. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at https://baseballnewssource.com/markets/quinn-opportunity-partners-llc-cuts-position-in-ophthotech-corporation-opht/1601969.html.

Separately, Stifel Nicolaus reiterated a “hold” rating and set a $4.00 target price on shares of Ophthotech Corporation in a research report on Thursday. Twelve equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $46.58.

Shares of Ophthotech Corporation (NASDAQ OPHT) opened at 2.69 on Friday. Ophthotech Corporation has a 12-month low of $2.24 and a 12-month high of $59.46. The company has a 50 day moving average price of $2.73 and a 200-day moving average price of $2.83. The firm’s market cap is $96.68 million.

Ophthotech Corporation (NASDAQ:OPHT) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.07) by $0.45. The company had revenue of $1.66 million for the quarter, compared to analyst estimates of $1.38 million. During the same quarter in the prior year, the business earned ($0.85) EPS. Ophthotech Corporation’s revenue was down 94.1% compared to the same quarter last year. Analysts expect that Ophthotech Corporation will post $0.29 EPS for the current year.

Ophthotech Corporation Company Profile

Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.

Institutional Ownership by Quarter for Ophthotech Corporation (NASDAQ:OPHT)

Receive News & Ratings for Ophthotech Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech Corporation and related companies with our FREE daily email newsletter.

 


Latest News

American League Once Again Dominates National League
American League Once Again Dominates National League
Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22


Leave a Reply

 
© 2006-2017 BBNS.